• Home
  • » 
  • Reports
  • » 
  • Liposome Development and Manufacturing S...

Liposome Manufacturing Market

Liposome Development and Manufacturing Services Market: Distribution by Type of Product Formulation (Therapeutic and Nutraceutical), Scale of Operation (Discovery / Research, Preclinical, Clinical and Commercial), End User (Pharmaceutical and Biotechnology, Cosmetics, Food, Agricultural, Academic and Other Industries), Key Geographical Regions (North America, Europe, Asia-Pacific, Middle East and North Africa and Latin America): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    January 2023

  • Pages
    232

  • View Count
    3441

  • Buy Now

Example Insights

Liposome-Development-and-Manufacturing-Services-Market-Context-thumb Liposome-Development-and-Manufacturing-Services-Market-List-of-Service-Providers-thumb Liposome-Development-and-Manufacturing-Services-Market-Distribution-by-Type-of-Service(s)-Offered-thumb
Liposome-Development-and-Manufacturing-Services-Market-Patent-Analysis-thumb Liposome-Development-and-Manufacturing-Services-Market-Global-Event-Analysis-thumb Liposome-Development-and-Manufacturing-Services-Market-Clinical-Trial-Analysis-thumb
Liposome-Development-and-Manufacturing-Services-Market-Publication-Analysis-thumb Liposome-Development-and-Manufacturing-Services-Market-Liposome-based-Therapeutic-Developers-thumb Liposome-Development-and-Manufacturing-Services-Market-Opportunity-thumb

 

Report Description

Around 90% of the drug candidates in the current development pipeline and close to 40% of marketed pharmacological products, have concerns related to solubility and / or permeability. Therefore, players engaged in the pharmaceutical industry are actively trying to identify ways to improve / augment physiochemical properties and drug-like behavior of pharmacological products. Amidst other alternatives, liposomes (which improve permeability across biological membranes), have garnered the attention of drug developers. Liposomes are small artificial vesicles that have the ability to encapsulate, deliver and release low-soluble drugs and small molecules to a specific site in the body. Over time, various research studies have demonstrated the potential of liposomes in disease diagnosis and drug delivery applications, owing to their ability to self-assemble, carry large drug payloads, act as biomarkers for various diseases and transport important functional elements. Given the various benefits, liposomes have gained significant interest in the biopharmaceutical industry, which is anticipated to increase their demand in future. However, the liposome development and liposome manufacturing is associated with several challenges, including complex manufacturing processes, huge capital investments, inadequate clinical grade production and GMP compliant industrial scale-up, lack of facilities with necessary infrastructure, as well as concerns related to storage and stability. Therefore, considering the aforementioned challenges, a number of pharmaceutical companies have demonstrated the preference to outsource their respective liposome development and liposome manufacturing operations to specialized service providers.

Q1. What is the Current Market Landscape of the Liposome Development and Manufacturing Services Market?
The liposome development / liposome manufacturing services market is amongst one of the most dynamic sectors of the biopharmaceutical industry. Presently, more than 70 companies have the required capabilities to offer liposome development and manufacturing services across different geographical locations. These service providers employ a variety of analysis and characterization methods for liposome development.

Liposome-Development-and-Manufacturing-Services-Market-Distribution-by-Scale-of-Operation

Q2. How has Outsourcing Evolved in the Liposome Development / Liposome Manufacturing Domain?
The manufacturing of highly potent liposome-based therapeutics requires an adequate working environment (to prevent cross contamination within multi-product assets), stringent manufacturing protocols (to comply with the established regulatory standards) and a trained workforce (to satisfactorily handle highly potent materials). In addition, it requires an expensive infrastructure, which is often complex to engineer, install and maintain. As a result, various companies rely on third party service providers to leverage their technologies for manufacturing these therapeutics and achieve greater operational flexibility. The inherent expertise of CMOs is believed to be capable of enabling reduction in the time-to-market a product and offer significant cost-benefits.

Q3. What are the Recent Developments and Expected Trends in the Liposome Development and Manufacturing domain?
In recent years, several events have been organized by various researchers / industry stakeholders in order to consolidate their presence in this field and enhance their existing capabilities to meet the growing demand for these novel drug delivery systems. It is worth mentioning that majority of the events were focused on discussing the analytical method development, manufacturing and process development steps for liposomes.

Liposome-Development-and-Manufacturing-Services-Market-Key-Focus-Area

Q4. What are the Key Challenges faced by Liposome Development and Manufacturing Service Providers?
The primary challenge faced by these service providers is associated with the poor stability of liposomes under shelf and in vivo conditions. This is mainly caused by the possibility of lipid oxidation and hydrolysis, leakage and loss of hydrophilic cargos, along with fission and fusion of particles. Currently, some of these issues can be overcome by experimenting with formulation adjuvants, including antioxidants, or post-preparation processing, such as freeze-thawing and freeze-drying. Further, since the manufacturing of liposomes on large-scale is a multi-step and multi-test process, therefore, innovation in this domain is essential in order to overcome the challenges.

Q5. What are the Key Value Drivers in the Liposome Development and Manufacturing Services Market?
The increasing demand for novel drug delivery systems for effective delivery has led to a rise in the number of liposome-based therapeutics in the overall biopharmaceutical development pipeline. In order to cater to the growing demand for such therapeutics, there is a requirement for safe manufacturing technologies. Although some biopharmaceutical companies have made considerable investments to establish in-house capabilities, the capital-intensive nature and specialized containment requirements make the role of contract manufacturers crucial, specifically for small and mid-sized developers.

Q6. What is the Current Market Scenario and Likely Growth associated with the Liposome Development and Manufacturing Services Domain?
The liposome development and manufacturing services market is anticipated to grow at a steady pace in the coming years. Among various other types of product formulations, the therapeutic formulations of liposomes are anticipated to capture the maximum share. Further, in terms of end-users, the pharmaceutical and biotechnology industry stakeholders are most likely to outsource their liposome development and manufacturing operations to service providers as these companies primarily employ liposomes at commercial scale for delivering drugs to the target sites. Specifically, in terms of geography, the liposome development and manufacturing services market in Latin America is likely to grow at a relatively faster pace in the long term.

Liposome-Development-and-Manufacturing-Services-Market-Forecast

Scope of the Report

The “Liposome Development and Manufacturing Services Market, 2022-2035: Distribution by Type of Product Formulation (Therapeutic and Nutraceutical), Scale of Operation (Discovery / Research, Preclinical, Clinical and Commercial), End User (Pharmaceutical and Biotechnology, Cosmetics,    Food, Agricultural, Academic and Other Industries), Key Geographical Regions (North America, Europe, Asia-Pacific, Middle East and North Africa and Latin America): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current market landscape and future potential of the liposome development and manufacturing services market, over the next decade. The study features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in providing liposome development and manufacturing services. Amongst other elements, the report includes:

  • An executive summary of the insights captured during our research. It offers a high-level view on the current state of liposome development and manufacturing services market and its likely evolution in the mid-long term.
  • A general overview of liposomes, along with information on the formation and classification of liposomes. Further, the chapter also lays emphasis on liposome as a drug delivery system, liposomal drug delivery platforms and therapeutic applications of liposomes in drug delivery. Additionally, it highlights the methods for liposome preparation, post-preparation treatments, liposome analysis and characterization methods, pharmaceutical and industrial applications of liposomes. Further, it also features a discussion on the challenges in this domain and need for outsourcing of liposome development and manufacturing operations.
  • A detailed assessment of the overall market landscape of liposome development and manufacturing service providers, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), region of headquarters, types of method(s) for liposome preparation, type of service(s) offered (formulation development, analytical method development, contract manufacturing, process development, quality control, GMP manufacturing, characterization, fill / finish, clinical and regulatory support, feasibility studies, screening and liposome conjugation), liposome bioconjugation target(s) (protein, small molecule, lipid, peptide, nucleic acid, vaccine antigen, vitamin, oligonucleotide, carbohydrate and mineral), scalability (small, mid and large), liposome analysis and characterization method(s) (stability analysis, encapsulation efficiency determination, size analysis, drug release kinetics, lipid content analysis, lamellarity analysis and permeability analysis), application(s) of liposomes (drug delivery, cancer therapy and gene therapy), scale of operation (discovery / research, preclinical, clinical and commercial) and end user (s) (pharmaceutical and biotechnology, food, academic, cosmetics, agricultural and other industries).
  • Elaborate profiles of the prominent (shortlisted based on a proprietary criterion) players offering liposome development and manufacturing services, across North America, Europe and Asia-Pacific. Each profile features a brief overview of the company, its financial information (if available), information on its service portfolio, recent developments and an informed future outlook.
  • A detailed analysis of completed, ongoing and planned clinical studies related to liposomes, highlighting prevalent trends across different parameters, such as trial registration year, trial status, trial registration year and patients enrolled, trial phase, type of sponsor / collaborator, study design, leading players (in terms of number of trials conducted), disease indication(s), popular therapeutic areas, type of treatment, emerging focus areas and regional distribution of trials (in terms of number of trials conducted and trial status).
  • A detailed review of more than 6,000 peer-reviewed, scientific articles related to research on liposomes, based on several relevant parameters, such as year of publication, application area(s), and emerging focus areas. The chapter also highlights the top journals (in terms of number of publications and impact factor).
  • An insightful analysis of the patents filed / granted for liposomes, since 2017, taking into consideration various relevant parameters, such as type of patent, patent publication year, granted patents and patent applications, geography, CPC symbols, emerging focus areas, type of organization, leading players (in terms of number of patents granted / filed) and patent characteristics. In addition, the chapter includes a detailed patent benchmarking and an insightful valuation analysis, highlighting the leading patents (in terms of number of citations).
  • An in-depth analysis of recent events (webinars / conferences / seminars / workshops / symposiums / summits) that were organized for stakeholders in this domain, based on several relevant parameters, such as year of event, event platform, type of event, geography, evolutionary trends in event agenda, most active event organizers, active industry and non-industry players (in terms of number of events that each company participated in), seniority level of event speakers, affiliated department of event speakers, most active speakers (in terms of number of events) and a geographical mapping of upcoming events.
  • An insightful outsourcing: go / no-go framework analysis, highlighting the various factors that need to be taken into consideration by liposome developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO. Further, the analysis highlights all the key parameters that must be considered by players based on company sizes (very small, small, mid-sized, large and very large), while taking the aforementioned decision.

One of the key objectives of the report was to evaluate the current opportunity and the future growth potential associated with the liposome development and manufacturing services market, over the coming years. We have provided informed estimates on the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as type of product formulation (therapeutic and nutraceutical), scale of operation (discovery / research, preclinical, clinical and commercial), end user (pharmaceutical and biotechnology, cosmetics, food, agricultural, academic and other industries), key geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa and Latin America). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Frequently Asked Questions

  • What is a liposome?
  • Who are the prominent players offering liposome development and manufacturing services?
  • What is the evolving trend of publications focused on liposomes?
  • How many patents, related to liposomes, have been filed / granted in the past few years?
  • Which companies are actively involved in conducting clinical trials for liposomes?
  • What are the key agenda items being discussed in various global events / conferences related to liposomes?
  • Which factors are likely to influence the decision of liposome manufacturing being done in-house or outsourced?
  • How is the current and future market opportunity related to liposome development and manufacturing services, likely to be distributed across key market segments?

Contents

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Liposomes
3.3. Formation of Liposomes
3.4. Classification of Liposomes
3.5. Liposome as a Drug Delivery System
3.5.1. Liposomal Drug Delivery Platforms
3.5.2. Therapeutic Applications of Liposomes in Drug Delivery

3.6. Methods for Liposome Preparation
3.7. Post-Preparation Treatments
3.7.1. Freeze-Thawing
3.7.2. Freeze-Drying

3.8. Liposome Analysis and Characterization Methods
3.9. Pharmaceutical and Industrial Applications of Liposomes
3.9.1. Drug Delivery
3.9.2. Gene Delivery
3.9.3. Vaccine Delivery
3.9.4. Cancer Therapy
3.9.5. Agricultural Industry
3.9.6. Cosmetics
3.9.7. Food Industry

3.10. Challenges in Liposome Development and Manufacturing
3.11. Need for Outsourcing of Liposome Development and Manufacturing
3.12. Future Perspectives

4. MARKET LANDSCAPE: LIPOSOME DEVELOPMENT AND LIPOSOME MANUFACTURING SERVICE PROVIDERS
4.1. Chapter Overview
4.2. Liposome Development and Liposome Manufacturing Service Providers Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Region of Headquarters
4.2.4. Analysis by Company Size and Region of Headquarters
4.2.5. Analysis by Type of Method(s) Used for Liposome Preparation
4.2.6. Analysis by Type of Service(s) Offered
4.2.7. Analysis by Liposome Bioconjugation Target(s)
4.2.8. Analysis by Scalability
4.2.9. Analysis by Liposome Analysis and Characterization Method(s)
4.2.10. Analysis by Application(s) of Liposomes
4.2.11. Analysis by Type of Service(s) Offered, Application(s) and Product Formulation
4.2.12. Analysis by Scale of Operation
4.2.13. Analysis by End User(s)
4.2.14. Analysis by Scale of Operation and End User(s)

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Key Players Based in North America
5.2.1. Baxter BioPharma Solutions
5.2.1.1. Company Overview
5.2.1.2. Financial Information
5.2.1.3. Service Portfolio
5.2.1.4. Recent Developments and Future Outlook

5.2.2. Charles River Laboratories
5.2.2.1. Company Overview
5.2.2.2. Financial Information
5.2.2.3. Service Portfolio
5.2.2.4. Recent Developments and Future Outlook

5.3. Key Players Based in Europe
5.3.1. Evonik
5.3.1.1. Company Overview
5.3.1.2. Financial Information
5.3.1.3. Service Portfolio
5.3.1.4. Recent Developments and Future Outlook

5.3.2. Fresenius Kabi
5.3.2.1. Company Overview
5.3.2.2. Financial Information
5.3.2.3. Service Portfolio
5.3.2.4. Recent Developments and Future Outlook

5.3.3. GEA
5.3.3.1. Company Overview
5.3.3.2. Financial Information
5.3.3.3. Service Portfolio
5.3.3.4. Recent Developments and Future Outlook

5.3.4. Intertek
5.3.4.1. Company Overview
5.3.4.2. Financial Information
5.3.4.3. Service Portfolio
5.3.4.4. Recent Developments and Future Outlook

5.4. Key Players Based in Asia-Pacific
5.4.1. Fujifilm
5.4.1.1. Company Overview
5.4.1.2. Financial Information
5.4.1.3. Service Portfolio
5.4.1.4. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Liposomes: Clinical Trial Analysis
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Trial Status
6.3.3. Analysis by Trial Registration Year and Trial Status
6.3.4. Analysis by Trial Registration Year and Patients Enrolled
6.3.5. Analysis by Trial Phase
6.3.6. Analysis by Trial Phase and Patients Enrolled
6.3.7. Analysis by Type of Sponsor / Collaborator
6.3.8. Analysis by Study Design
6.3.9. Most Active Industry Players: Analysis by Number of Trials
6.3.10. Most Active Non-Industry Players: Analysis by Number of Trials
6.3.11. Most Popular Disease Indication(s): Analysis by Number of Trials
6.3.12. Most Popular Therapeutic Areas(s): Analysis by Number of Trials
6.3.13. Analysis by Type of Treatment
6.3.14. Word Cloud Analysis: Emerging Focus Areas
6.3.15. Analysis by Top Indication(s) and Trial Phase
6.3.16. Analysis by Top Indication(s) and Leading Industry Players
6.3.17. Geographical Analysis by Number of Clinical Trials
6.3.18. Geographical Analysis by Number of Patients Enrolled

7. PUBLICATION ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Liposomes: Recent Publications
7.3.1. Analysis by Year of Publication
7.3.2. Analysis by Application Area(s)
7.3.3. Word Cloud Analysis: Emerging Focus Areas
7.3.4. Key Journals: Analysis by Number of Publications
7.3.5. Key Journals: Analysis by Impact Factor
7.3.6. Key Journals: Analysis by Year-wise Number of Publications

8. PATENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Liposomes: Patent Analysis
8.3.1. Analysis by Patent Publication Year
8.3.2. Analysis by Granted Patents and Patent Applications
8.3.3. Analysis by Geography
8.3.4. Analysis by CPC Symbols
8.3.5. Word Cloud Analysis: Emerging Focus Areas
8.3.6. Analysis by Type of Organization
8.3.7. Leading Industry Players: Analysis by Number of Patents
8.3.8. Leading Non-Industry Players: Analysis by Number of Patents
8.3.9. Leading Individual Assignees: Analysis by Number of Patents

8.4. Liposomes: Patent Benchmarking Analysis
8.4.1. Analysis by Patent Characteristics

8.5. Liposomes: Patent Valuation Analysis
8.6. Leading Patents: Analysis by Number of Citations

9. GLOBAL EVENT ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Liposome Development and Liposome Manufacturing: Global Events Analysis
9.3.1. Analysis by Year of Event
9.3.2. Analysis by Event Platform
9.3.3. Analysis by Type of Event
9.3.4. Analysis by Year of Event and Type of Event
9.3.5. Analysis by Geography
9.3.6. Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Area
9.3.7. Most Active Event Organizers

9.4. Liposome Development and Liposome Manufacturing: Speaker Analysis
9.4.1. Most Active Industry Players: Analysis by Number of Events
9.4.2. Most Active Non-Industry Players: Analysis by Number of Events
9.4.3. Analysis by Seniority Level of Event Speakers
9.4.4. Analysis by Affiliated Department of Event Speakers
9.4.5. Most Active Speakers: Analysis by Number of Events

9.5. Geographical Mapping of Upcoming Events
9.6. Concluding Remarks

10. OUTSOURCING: GO / NO-GO FRAMEWORK
10.1. Chapter Overview
10.2. Outsourcing: Go / No-Go Framework
10.3. Liposome-based Therapeutic Developers Outsourcing: Go / No-Go Framework
10.3.1. Key Parameters and Assumptions
10.3.2. Methodology
10.3.3. Results and Interpretations
10.3.3.1. Very Small Companies
10.3.3.2. Small Companies
10.3.3.3. Mid-Sized Companies
10.3.3.4. Large Companies
10.3.3.5. Very Large Companies

11. MARKET FORECAST AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Global Liposome Development and Liposome Manufacturing Services Market, 2022-2035
11.3.1. Liposome Development and Liposome Manufacturing Services Market: Distribution by Type of Product Formulation, 2022 and 2035
11.3.1.1. Liposome Development and Manufacturing Services Market for Therapeutics, 2022-2035
11.3.1.2. Liposome Development and Manufacturing Services Market for Nutraceuticals, 2022-2035

11.3.2. Liposome Development and Liposome Manufacturing Services Market: Distribution by Scale of Operation, 2022 and 2035
11.3.2.1. Liposome Development and Manufacturing Services Market for Discovery / Research Scale of Operation, 2022-2035
11.3.2.2. Liposome Development and Manufacturing Services Market for Preclinical Scale of Operation, 2022-2035
11.3.2.3. Liposome Development and Manufacturing Services Market for Clinical Scale of Operation, 2022-2035
11.3.2.4. Liposome Development and Manufacturing Services Market for Commercial Scale of Operation, 2022-2035

11.3.3. Liposome Development and Manufacturing Services Market: Distribution by End User, 2022 and 2035
11.3.3.1. Liposome Development and Manufacturing Services Market for Pharmaceutical and Biotechnology Industry, 2022-2035
11.3.3.2. Liposome Development and Manufacturing Services Market for Food Industry, 2022-2035
11.3.3.3. Liposome Development and Manufacturing Services Market for Agricultural Industry, 2022-2035
11.3.3.4. Liposome Development and Manufacturing Services Market for Cosmetic Industry, 2022-2035
11.3.3.5. Liposome Development and Manufacturing Services Market for Academics, 2022-2035
11.3.3.6. Liposome Development and Manufacturing Services Market for Other Industries, 2022-2035

11.3.4. Liposome Development and Liposome Manufacturing Services Market: Distribution by Key Geographical Regions, 2022 and 2035
11.3.4.1. Liposome Development and Manufacturing Services Market in North America, 2022-2035
11.3.4.2. Liposome Development and Manufacturing Services Market in Europe, 2022-2035
11.3.4.3. Liposome Development and Manufacturing Services Market in Asia-Pacific, 2022-2035
11.3.4.4. Liposome Development and Manufacturing Services Market in Middle East and North Africa, 2022-2035
11.3.4.5. Liposome Development and Manufacturing Services Market in Latin America, 2022-2035

12. CONCLUDING REMARKS

13. EXECUTIVE INSIGHTS

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Liposome Development and Manufacturing Service Providers Landscape
Figure 2.2 Executive Summary: Clinical Trial Analysis
Figure 2.3 Executive Summary: Publication Analysis
Figure 2.4 Executive Summary: Patent Analysis
Figure 2.5 Executive Summary: Global Event Analysis
Figure 2.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Formation of Liposomes
Figure 3.2 Liposomal Drug Delivery Platforms
Figure 3.3 Therapeutic Applications of Liposomes in Drug Delivery
Figure 3.4 Methods for Liposome Preparation
Figure 3.5 Liposomal Analysis and Characterization Methods
Figure 3.6 Pharmaceutical and Industrial Applications of Liposomes
Figure 4.1 Liposome Development and Manufacturing Service Providers: Distribution by Year of Establishment
Figure 4.2 Liposome Development and Manufacturing Service Providers: Distribution by Company Size
Figure 4.3 Liposome Development and Manufacturing Service Providers: Distribution by Region of Headquarters
Figure 4.4 Liposome Development and Manufacturing Service Providers: Distribution by Location of Headquarters
Figure 4.5 Liposome Development and Manufacturing Service Providers: Distribution by Company Size and Region of Headquarters
Figure 4.6 Liposome Development and Manufacturing Service Providers: Distribution by Type of Method(s) Used for Liposome Preparation
Figure 4.7 Liposome Development and Manufacturing Service Providers: Distribution by Type of Service(s) Offered
Figure 4.8 Liposome Development and Manufacturing Service Providers: Distribution by Liposome Bioconjugation Target(s)
Figure 4.9 Liposome Development and Manufacturing Service Providers: Distribution by Scalability
Figure 4.10 Liposome Development and Manufacturing Service Providers: Distribution by Liposome Analysis and Characterization Method(s)
Figure 4.11 Liposome Development and Manufacturing Service Providers: Distribution by Application(s) of Liposomes
Figure 4.12 Liposome Development and Manufacturing Service Providers: Distribution by Type of Service(s) Offered, Application(s) and Product Formulation
Figure 4.13 Liposome Development and Manufacturing Service Providers: Distribution by Scale of Operation
Figure 4.14 Liposome Development and Manufacturing Service Providers: Distribution by End User(s)
Figure 4.15 Liposome Development and Manufacturing Service Providers: Distribution by Scale of Operation and End User(s)
Figure 5.1 Baxter BioPharma Solutions: Annual Revenues, 2017-9M 2022 (USD Billion)
Figure 5.2 Charles River Laboratories: Annual Revenues, 2017-9M 2022 (USD Billion)
Figure 5.3 Evonik: Annual Revenues, 2017-9M 2022 (EUR Billion)
Figure 5.4 Fresenius Kabi: Annual Revenues, 2017-9M 2022 (EUR Billion)
Figure 5.5 GEA: Annual Revenues, 2017-9M 2022 (EUR Billion)
Figure 5.6 Intertek: Annual Revenues, 2017-H1 2022 (EUR Billion)
Figure 5.7 Fujifilm: Annual Revenues, FY 2017-H1 FY 2022 (JPY Trillion)
Figure 6.1 Clinical Trial Analysis: Scope and Methodology
Figure 6.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2016-2022
Figure 6.3 Clinical Trial Analysis: Distribution by Trial Status
Figure 6.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2001-2022
Figure 6.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled, 2016-2022
Figure 6.6 Clinical Trial Analysis: Distribution by Trial Phase
Figure 6.7 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
Figure 6.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 6.9 Clinical Trial Analysis: Distribution by Study Design
Figure 6.10 Most Active Industry Players: Distribution by Number of Trials
Figure 6.11 Most Active Non-Industry Players: Distribution by Number of Trials
Figure 6.12 Most Popular Disease Indication(s): Distribution by Number of Trials
Figure 6.13 Most Popular Therapeutic Area(s): Distribution by Number of Trials
Figure 6.14 Clinical Trial Analysis: Distribution by Type of Treatment
Figure 6.15 Word Cloud Analysis: Emerging Focus Areas
Figure 6.16 Clinical Trial Analysis: Distribution by Top Indication(s) and Trial Phase
Figure 6.17 Clinical Trial Analysis: Distribution by Top Indication(s) and Leading Industry Players
Figure 6.18 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Figure 6.19 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Figure 7.1 Publication Analysis: Cumulative Year-wise Trend, 2017-2022
Figure 7.2 Publication Analysis: Distribution by Application Area(s)
Figure 7.3 Word Cloud Analysis: Emerging Focus Areas
Figure 7.4 Key Journals: Distribution by Number of Publications
Figure 7.5 Key Journals: Distribution by Impact Factor
Figure 7.6 Key Journals: Year-wise Distribution by Number of Publications
Figure 8.1 Patent Analysis: Distribution by Type of Patent
Figure 8.2 Patent Analysis: Cumulative Distribution by Patent Publication Year, 2017-2022
Figure 8.3 Patent Analysis: Year-wise Distribution by Granted Patents and Patent Applications, 2017-2022
Figure 8.4 Patent Analysis: Distribution by Geography
Figure 8.5 Patent Analysis: Distribution by CPC Sections
Figure 8.6 Word Cloud Analysis: Emerging Focus Areas
Figure 8.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization, 2017-2022
Figure 8.8 Leading Industry Players: Distribution by Number of Patents
Figure 8.9 Leading Non-Industry Players: Distribution by Number of Patents
Figure 8.10 Leading Individual Assignees: Distribution by Number of Patents
Figure 8.11 Leading Players: Benchmarking by Patent Characteristics (CPC Codes)
Figure 8.12 Patent Analysis: Distribution by Patent Age
Figure 8.13 Liposomes: Patent Valuation Analysis
Figure 9.1 Global Event Analysis: Cumulative Year-wise Trend, 2017-2022
Figure 9.2 Global Event Analysis: Distribution by Event Platform
Figure 9.3 Global Event Analysis: Distribution by Type of Event
Figure 9.4 Global Event Analysis: Distribution by Year of Event and Type of Event
Figure 9.5 Global Event Analysis: Distribution by Location of Events
Figure 9.6 Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Area
Figure 9.7 Global Event Analysis: Historical Trend of Event Agendas, 2017-2022
Figure 9.8 Most Active Organizers: Distribution by Number of Events
Figure 9.9 Most Active Industry Players: Distribution by Number of Events
Figure 9.10 Most Active Non-Industry Players: Distribution by Number of Events
Figure 9.11 Seniority Level of Event Speakers: Distribution by Number of Events
Figure 9.12 Affiliated Department of Event Speakers: Distribution by Number of Events
Figure 9.13 Most Active Speakers: Distribution by Number of Events
Figure 9.14 Global Event Analysis: Geographical Mapping of Upcoming Events
Figure 10.1 Outsourcing: Go / No-Go Framework
Figure 10.2 Outsourcing: Go / No-Go Framework Methodology
Figure 10.3 Outsourcing: Go / No-Go Framework for Liposome-based Therapeutic Developers
Figure 10.4 Liposome-based Therapeutic Developers: Benchmarking of Very Small Companies
Figure 10.5 Liposome-based Therapeutic Developers: Benchmarking of Small Companies
Figure 10.6 Liposome-based Therapeutic Developers: Benchmarking of Mid-Sized Companies
Figure 10.7 Liposome-based Therapeutic Developers: Benchmarking of Large Companies
Figure 10.8 Liposome-based Therapeutic Developers: Benchmarking of Very Large Companies
Figure 11.1 Global Liposome Development and Manufacturing Services Market, 2022-2035 (USD Billion)
Figure 11.2 Liposome Development and Manufacturing Services Market: Distribution by Type of Product Formulation, 2022 and 2035
Figure 11.3 Liposome Development and Manufacturing Services Market for Therapeutics, 2022-2035 (USD Billion)
Figure 11.4 Liposome Development and Manufacturing Services Market for Nutraceuticals, 2022-2035 (USD Billion)
Figure 11.5 Liposome Development and Manufacturing Services Market: Distribution by Scale of Operation, 2022 and 2035
Figure 11.6 Liposome Development and Manufacturing Services Market for Discovery / Research Scale of Operation, 2022-2035 (USD Billion)
Figure 11.7 Liposome Development and Manufacturing Services Market for Preclinical Scale of Operation, 2022-2035 (USD Billion)
Figure 11.8 Liposome Development and Manufacturing Services Market for Clinical Scale of Operation, 2022-2035 (USD Billion)
Figure 11.9 Liposome Development and Manufacturing Services Market for Commercial Scale of Operation, 2022-2035 (USD Billion)
Figure 11.10 Liposome Development and Manufacturing Services Market: Distribution by End User, 2022 and 2035
Figure 11.11 Liposome Development and Manufacturing Services Market for Pharmaceutical and Biotechnology Industry, 2022-2035 (USD Billion)
Figure 11.12 Liposome Development and Manufacturing Services Market for Food Industry, 2022-2035 (USD Billion)
Figure 11.13 Liposome Development and Manufacturing Services Market for Agricultural Industry, 2022-2035 (USD Billion)
Figure 11.14 Liposome Development and Manufacturing Services Market for Cosmetic Industry, 2022-2035 (USD Billion)
Figure 11.15 Liposome Development and Manufacturing Services Market for Academics, 2022-2035 (USD Billion)
Figure 11.16 Liposome Development and Manufacturing Services Market for Other Industries, 2022-2035 (USD Billion)
Figure 11.17 Liposome Development and Manufacturing Services Market: Distribution by Key Geographical Regions, 2022 and 2035
Figure 11.18 Liposome Development and Manufacturing Services Market in North America, 2022-2035 (USD Billion)
Figure 11.19 Liposome Development and Manufacturing Services Market in Europe, 2022-2035 (USD Billion)
Figure 11.20 Liposome Development and Manufacturing Services Market in Asia-Pacific, 2022-2035 (USD Billion)
Figure 11.21 Liposome Development and Manufacturing Services Market in Middle East and North Africa, 2022-2035 (USD Billion)
Figure 11.22 Liposome Development and Manufacturing Services Market in Latin America, 2022-2035 (USD Billion)
Figure 12.1 Concluding Remarks: Liposome Development and Manufacturing Service Providers Market Landscape
Figure 12.2 Concluding Remarks: Clinical Trial Analysis
Figure 12.3 Concluding Remarks:Publication Analysis
Figure 12.4 Concluding Remarks: Patent Analysis
Figure 12.5 Concluding Remarks: Global Event Analysis
Figure 12.6 Concluding Remarks: Market Forecast and Opportunity Analysis

List Of Tables

Table 3.1 Classification of Liposomes
Table 4.1 List of Liposome Development and Manufacturing Service Providers
Table 4.2 Liposome Development and Manufacturing Service Providers: Information on Type of Method(s) Used for Liposome Preparation
Table 4.3 Liposome Development and Manufacturing Service Providers: Information on Type of Service(s) Offered
Table 4.4 Liposome Development and Manufacturing Service Providers: Information on Liposome Bioconjugation Target(s)
Table 4.5 Liposome Development and Manufacturing Service Providers: Information on Scalability, and Liposome Analysis and Characterization Method(s)
Table 4.6 Liposome Development and Manufacturing Service Providers: Information on Application(s) and Scale of Operation
Table 4.7 Liposome Development and Manufacturing Service Providers: Information on End User(s)
Table 5.1 Liposome Service Providers: List of Companies Profiled
Table 5.2 Baxter BioPharma Solutions: Company Snapshot
Table 5.3 Baxter BioPharma Solutions: Service Portfolio
Table 5.4 Baxter BioPharma Solutions: Recent Developments and Future Outlook
Table 5.5 Charles River Laboratories: Company Snapshot
Table 5.6 Charles River Laboratories: Service Portfolio
Table 5.7 Charles River Laboratories: Recent Developments and Future Outlook
Table 5.8 Evonik: Company Snapshot
Table 5.9 Evonik: Service Portfolio
Table 5.10 Evonik: Recent Developments and Future Outlook
Table 5.11 Fresenius Kabi: Company Snapshot
Table 5.12 Fresenius Kabi: Service Portfolio
Table 5.13 GEA: Company Snapshot
Table 5.14 GEA: Service Portfolio
Table 5.15 Intertek: Company Snapshot
Table 5.16 Intertek: Service Portfolio
Table 5.17 Intertek: Recent Developments and Future Outlook
Table 5.18 Fujifilm: Company Snapshot
Table 5.19 Fujifilm: Service Portfolio
Table 5.20 Fujifilm: Recent Developments and Future Outlook
Table 8.1 Patent Analysis: Top CPC Sections
Table 8.2 Patent Analysis: Top Five CPC Symbols
Table 8.3 Patent Analysis: Top Six CPC Codes
Table 8.4 Patent Analysis: Summary of Benchmarking Analysis
Table 8.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 8.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 8.7 Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 9.1 List of Global Events related to Liposome Development and Manufacturing
Table 13.1 Midwestern University: Organization Snapshot
Table 14.1 Liposome Development and Manufacturing Service Providers: Distribution by Year of Establishment
Table 14.2 Liposome Development and Manufacturing Service Providers: Distribution by Company Size
Table 14.3 Liposome Development and Manufacturing Service Providers: Distribution by Region of Headquarters
Table 14.4 Liposome Development and Manufacturing Service Providers: Distribution by Location of Headquarters
Table 14.5 Liposome Development and Manufacturing Service Providers: Distribution by Company Size and Region of Headquarters
Table 14.6 Liposome Development and Manufacturing Service Providers: Distribution by Type of Method(s) Used for Liposome Preparation
Table 14.7 Liposome Development and Manufacturing Service Providers: Distribution by Type of Service(s) Offered
Table 14.8 Liposome Development and Manufacturing Service Providers: Distribution by Liposome Bioconjugation Target(s)
Table 14.9 Liposome Development and Manufacturing Service Providers: Distribution by Scalability
Table 14.10 Liposome Development and Manufacturing Service Providers: Distribution by Liposome Analysis and Characterization Method(s)
Table 14.11 Liposome Development and Manufacturing Service Providers: Distribution by Application(s) of Liposomes
Table 14.12 Liposome Development and Manufacturing Service Providers: Distribution by Scale of Operation
Table 14.13 Liposome Development and Manufacturing Service Providers: Distribution by End User(s)
Table 14.14 Liposome Development and Manufacturing Service Providers: Distribution by Scale of Operation and End User(s)
Table 14.15 Baxter BioPharma Solutions: Annual Revenues, 2017-9M 2022 (USD Billion)
Table 14.16 Charles River Laboratories: Annual Revenues, 2017-9M 2022 (USD Billion)
Table 14.17 Evonik: Annual Revenues, 2017-9M 2022 (EUR Billion)
Table 14.18 Fresenius Kabi: Annual Revenues, 2017-9M 2022 (EUR Billion)
Table 14.19 GEA: Annual Revenues, 2017-9M 2022 (EUR Billion)
Table 14.20 Intertek: Annual Revenues, 2017-H1 2022 (EUR Billion)
Table 14.21 Fujifilm: Annual Revenues, FY 2017-H1 FY 2022 (JPY Trillion)
Table 14.22 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2016-2022
Table 14.23 Clinical Trial Analysis: Distribution by Trial Status
Table 14.24 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2001-2022
Table 14.25 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled, 2016-2022
Table 14.26 Clinical Trial Analysis: Distribution by Trial Phase
Table 14.27 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
Table 14.28 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 14.29 Clinical Trial Analysis: Distribution by Study Design
Table 14.30 Most Active Industry Players: Distribution by Number of Trials
Table 14.31 Most Active Non-Industry Players: Distribution by Number of Trials
Table 14.32 Most Popular Disease Indication(s): Distribution by Number of Trials
Table 14.33 Most Popular Therapeutic Area(s): Distribution by Number of Trials
Table 14.34 Clinical Trial Analysis: Distribution by Type of Treatment
Table 14.35 Clinical Trial Analysis: Distribution by Top Indication(s) and Trial Phase
Table 14.36 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Table 14.37 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Table 14.38 Publication Analysis: Cumulative Year-wise Trend, 2017-2022
Table 14.39 Publication Analysis: Distribution by Application Area(s)
Table 14.40 Key Journals: Distribution by Number of Publications
Table 14.41 Key Journals: Distribution by Impact Factor
Table 14.42 Key Journals: Year-wise Distribution by Number of Publications
Table 14.43 Patent Analysis: Distribution by Type of Patent
Table 14.44 Patent Analysis: Cumulative Distribution by Patent Publication Year, 2017-2022
Table 14.45 Patent Analysis: Year-wise Distribution by Granted Patents and Patent Applications, 2017-2022
Table 14.46 Patent Analysis: Distribution by Geography
Table 14.47 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization, 2017-2022
Table 14.48 Leading Industry Players: Distribution by Number of Patents
Table 14.49 Leading Non-Industry Players: Distribution by Number of Patents
Table 14.50 Leading Individual Assignees: Distribution by Number of Patents
Table 14.51 Patent Analysis: Distribution by Patents Age
Table 14.52 Liposomes: Patent Valuation Analysis
Table 14.53 Global Event Analysis: Cumulative Year-wise Trend, 2017-2022
Table 14.54 Global Event Analysis: Distribution by Event Platform
Table 14.55 Global Event Analysis: Distribution by Type of Event
Table 14.56 Global Event Analysis: Distribution by Year of Event and Type of Event
Table 14.57 Global Event Analysis: Distribution by Location of Events
Table 14.58 Most Active Organizers: Distribution by Number of Events
Table 14.59 Most Active Industry Players: Distribution by Number of Events
Table 14.60 Most Active Non-Industry Players: Distribution by Number of Events
Table 14.61 Seniority Level of Event Speakers: Distribution by Number of Events
Table 14.62 Affiliated Department of Event Speakers: Distribution by Number of Events
Table 14.63 Most Active Speakers: Distribution by Number of Events
Table 14.64 Global Liposome Development and Manufacturing Services Market, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.65 Liposome Development and Manufacturing Services Market: Distribution by Type of Product Formulation, 2022 and 2035
Table 14.66 Liposome Development and Manufacturing Services Market for Therapeutics, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.67 Liposome Development and Manufacturing Services Market for Nutraceuticals, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.68 Liposome Development and Manufacturing Services Market: Distribution by Scale of Operation, 2022 and 2035
Table 14.69 Liposome Development and Manufacturing Services Market for Discovery / Research Scale of Operation, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.70 Liposome Development and Manufacturing Services Market for Preclinical Scale of Operation, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.71 Liposome Development and Manufacturing Services Market for Clinical Scale of Operation, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.72 Liposome Development and Manufacturing Services Market for Commercial Scale of Operation, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.73 Liposome Development and Manufacturing Services Market: Distribution by End User, 2022 and 2035
Table 14.74 Liposome Development and Manufacturing Services Market for Pharmaceutical and Biotechnology Industry, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.75 Liposome Development and Manufacturing Services Market for Food Industry, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.76 Liposome Development and Manufacturing Services Market for Agricultural Industry, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.77 Liposome Development and Manufacturing Services Market for Cosmetic Industry, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.78 Liposome Development and Manufacturing Services Market for Academics, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.79 Liposome Development and Manufacturing Services Market for Other Industries, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.80 Liposome Development and Manufacturing Services Market: Distribution by Key Geographical Regions, 2022 and 2035
Table 14.81 Liposome Development and Manufacturing Services Market in North America, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.82 Liposome Development and Manufacturing Services Market in Europe, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.83 Liposome Development and Manufacturing Services Market in Asia-Pacific, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.84 Liposome Development and Manufacturing Services Market in Middle East and North Africa, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.85 Liposome Development and Manufacturing Services Market in Latin America, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)

List Of Companies

The following companies and organizations have been mentioned in the report:

  1. AbbVie
  2. Acrotech Biopharma
  3. Advenchen Laboratories
  4. AGC Biologics
  5. Ajinomoto Bio-Pharma Services
  6. Alkermes
  7. Althea
  8. Altogen Labs
  9. ALX Oncology
  10. Alzeca Biosciences
  11. Amerigo Scientific
  12. Amgen
  13. APEIRON Biologics
  14. Aprea Therapeutics
  15. Aravive
  16. Arcus Biosciences
  17. Ardena
  18. Aronex Pharmaceuticals (acquired by Agenus)
  19. Array BioPharma
  20. Ascendia Pharmaceuticals
  21. Ascension
  22. Astellas Pharma
  23. Astex Pharmaceuticals
  24. AstraZeneca
  25. Atreca
  26. Aurobindo Pharma
  27. Avanti Polar Lipids
  28. AXIS Clinicals
  29. Ayana Pharma
  30. Azaya Therapeutics (a subsidiary of Plus Therapeutics)
  31. Baxter BioPharma Solutions
  32. Bayer
  33. Bharat Serums and Vaccines (BSV)
  34. Biofuture Medicine
  35. Biogen
  36. Biolipox (acquired by Orexo)
  37. BioNTech
  38. Bio-Path Holdings
  39. Biopharma Group
  40. BIOrest
  41. Bioserv
  42. BJP Laboratories
  43. BOC Sciences
  44. Boehringer Ingelheim
  45. Bristol Myers Squibb
  46. BSP Pharmaceuticals
  47. Callisto Pharmaceuticals
  48. CD Bioparticles
  49. CD Formulation
  50. Celgene
  51. Changzhou Jinyuan Pharmaceutical Manufacturing
  52. Charles River Laboratories
  53. Children's Medical Center
  54. Children's Oncology Group
  55. ClinAssess
  56. Conference Series
  57. Corden Pharma
  58. Creative Biogene
  59. Creative Biolabs
  60. Creative BioMart
  61. Creative Biostructure
  62. Crolll
  63. CSL Vifor
  64. CSPC Pharmaceutical Group
  65. Curia
  66. Dalton Pharma Services
  67. DIANT Pharma
  68. Dr. Reddy's Laboratories
  69. Eisai
  70. Eli Lilly and Company
  71. Emmes
  72. Empirial Labs
  73. Encapsula NanoSciences
  74. Endocyte
  75. Endovasc
  76. Esco Aster
  77. Essex Pharma
  78. eTheRNA
  79. Etico Lifesciences
  80. Eudinamis
  81. Eurofins Advinus
  82. Evonik
  83. Exelead
  84. Experior
  85. FormuMax Scientific
  86. Fovea Pharmaceuticals (a subsidiary of Sanofi)
  87. Fresenius Kabi
  88. Fudan University 
  89. FUJIFILM Pharmaceuticals
  90. Galenix Innovations (a subsidiary of Galenix)
  91. GEA
  92. Genelux
  93. Genovior Biotech
  94. Gilead Sciences
  95. GlaxoSmithKline
  96. GMPriority Pharma
  97. GP Pharm
  98. Gynecologic Oncology Group (GOG)
  99. HanAll Biopharma
  100. Heron Therapeutics
  101. ImmunityBio
  102. ImmunoGen
  103. IMUNON
  104. Incyte
  105. Inex Pharmaceuticals
  106. Infinity Pharmaceuticals
  107. InnoCan Pharma
  108. Innovent Biologics
  109. Insmed
  110. Insys Therapeutics
  111. Integral University
  112. Intertek
  113. Ipsen
  114. Janssen Pharmaceuticals (acquired by Johnson & Johnson)
  115. Janssen Research & Development (a part of Janssen Pharmaceuticals) 
  116. Jazz Pharmaceuticals
  117. Jiangsu Hengrui Medicine
  118. Karyopharm Therapeutics
  119. Katayama chemical
  120. Kyowa Pharma Chemical
  121. Lambda Therapeutic Research
  122. L.E.A.F. Pharmaceuticals
  123. LEAF4Life
  124. Leland Stanford Junior University
  125. LipExoGen
  126. LipoCellTech
  127. Lipomedix Pharmaceuticals
  128. LIPOSOMA
  129. Lotus Clinical Research
  130. Luye Pharma
  131. Malvern Panalytical
  132. Mango Pharmaceuticals
  133. Mayo Clinic
  134. MDS Pharma Services
  135. Mebiopharm
  136. MedServ
  137. MEDSIR
  138. Merck
  139. Merrimack
  140. Microfluidics (acquired by IDEX)
  141. Millennium Pharmaceuticals (acquired by Takeda)
  142. Moleculin Biotech
  143. Morphotek (a subsidiary of Eisai)
  144. Mundipharma
  145. NanoString Technologies
  146. NanoVation Therapeutics
  147. Nanovex Biotechnologies
  148. National Cancer Institute (NCI)
  149. NeXstar Pharmaceuticals (a subsidiary of Gilead Sciences)
  150. Nippon Fine Chemical
  151. Novartis
  152. Novo Nordisk
  153. Novotech
  154. Nuance Pharma
  155. NutraPak USA
  156. NYU Langone Health
  157. ONCOtherapeutics
  158. Ono Pharmaceutical
  159. OSI Pharmaceuticals (a subsidiary of Astellas Pharma)
  160. Pacira Pharmaceuticals
  161. Paladin Labs
  162. Parexel
  163. Parexo Labs (a subsidiary of Azaya Therapeutics) 
  164. Pensatech Pharma
  165. Pfizer
  166. PharmaMar
  167. Pharmatech
  168. PharmEvo
  169. Pharmosa BioPharm
  170. pharmtrace
  171. Piramal Pharma Solutions
  172. Pivotal
  173. PlantaCorp
  174. Plus Therapeutics
  175. Polymun Scientific
  176. Postnova Analytics
  177. PPD
  178. PreciGenome
  179. Precision NanoSystems
  180. ProFoldin
  181. ProJect Pharmaceutics
  182. PureNSM
  183. Roche
  184. Roswell Park Comprehensive Cancer Center
  185. S G Biopharm
  186. Sanofi
  187. Santa Maria Biotherapeutics
  188. Servier
  189. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
  190. Shattuck Labs
  191. Shenzhen Kangzhe Pharmaceutical
  192. Shilpa Medicare
  193. SignPath Pharma
  194. Simcere Pharmaceutical
  195. Spectrum Pharmaceuticals
  196. Sun Yat-sen University
  197. Supplement Manufacturing Partners (SMP Nutra)
  198. T&T Scientific
  199. Taiho Oncology
  200. Taiwan Liposome Company
  201. Telik (acquired by MabVax Therapeutics)
  202. Teva Pharmaceuticals
  203. The National and Kapodistrian University of Athens (NKUA)
  204. The University of British Columbia
  205. The University of Tennessee Health Science Center
  206. The University of Texas 
  207. Toray Engineering
  208. Transdermal Biotechnology 
  209. Translate Bio (a subsidiary of Sanofi)
  210. TriHealth
  211. TTY Biopharm
  212. University of California
  213. University of Minnesota
  214. University of Paris
  215. University of Pennsylvania
  216. University of Strathclyde
  217. University of Texas MD Anderson Cancer Center
  218. Valimenta Labs
  219. Vironova
  220. Walter Reed Army Institute of Research
  221. WiSP Wissenschaftlicher Service Pharma
  222. Wyatt Technology
  223. Yakult Honsha
  224. Yale University
  225. Yipinhong Pharmaceutical
  226. Yissum Research Development Company of the Hebrew University of Jerusalem
  227. YM BioSciences (a subsidiary of Gilead Sciences)
  228. Zambon
  229. Zeneus Pharma (acquired by Cephalon)
  230. ZoneOne Pharma

Source 1: https://www.pharmtech.com/view/adapting-to-solubility-bioavailability-challenges
Source 2: https://pubmed.ncbi.nlm.nih.gov/32650041/

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experience  Accept

Copyright © 2023 Roots Analysis. All Rights Reserved.